Monitor for actual sale execution; while this is a routine post-vesting sale, the context of recent insider buying ($8.8M) suggests broader confidence, making this isolated sale less concerning. No immediate price impact expected.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 14 $27.32entry
- T+1 · 7mo ago +11.35%α +10.57% · $30.42
- T+5 · 7mo ago +5.34%α +3.95% · $28.78
- T+20 · 6mo ago +8.82%α +2.53% · $29.73
- T+60 · 4mo ago +6.00%α −2.52% · $28.96
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Jon Congleton, an officer of Mineralys Therapeutics, filed a Form 144 to notify intent to sell 15,730 shares of common stock, which vested on April 10, 2026, as part of a restricted share unit award. The sale is planned through Merrill Lynch on Nasdaq.
Key Facts
- Jon Congleton, an officer, intends to sell 15,730 shares of MLYS common stock.
- Shares were acquired on April 10, 2026, due to vesting of restricted share units granted under the company's equity compensation plan.
- The filing was submitted on April 13, 2026, with Merrill Lynch listed as the broker.
- No sales have occurred yet; this is a notice of proposed sale.
- Recent insider activity shows $8.8M in buys and $579K in sells over the prior 30 days.
Financial Impact
Approximately $422,000 based on recent transaction value (reported $421,979.55).
Risk Factors
- Potential perception of negative sentiment if the sale executes near key catalysts or earnings.
- Limited liquidity risk given the relatively small share volume compared to market cap ($2.2B).
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001964306-26-000202 |
| Document: 0001964306-26-000202-index.html | 0001964306-26-000202 |
| Document: 0001964306-26-000202.txt | 0001964306-26-000202 |
Track record
35 reports on MLYS
4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +20.97% at T+20 after the Jun 11, 2026 report. 5 of 10 went positive at some point.
Filters
- Nov 8, 20268d ago Press Release Bullish 6/10 Entry $15.81 Now $14.53 −8.10% settles Dec 8
- Nov 4, 202612d ago 8-K Neutral 4/10 Entry $15.24 Now $14.53 −4.66% settles Dec 4
- Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $15.99 Now $14.53 −9.13% settles Dec 2
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $18.18 Now $14.53 −20.08% settles Nov 30
- Oct 28, 202619d ago Press Release Bullish 6/10 Entry $21.38 Now $14.53 −32.04% settles Nov 25
- Oct 20, 202627d ago 3 Neutral 2/10 Entry $21.10 Now $14.53 −31.14% settles Nov 18
- Oct 20, 202627d ago 3 Neutral 2/10 Entry $21.10 Now $14.53 −31.14% settles Nov 18
- Oct 19, 202628d ago 8-K Neutral 2/10 Entry $21.58 Now $14.53 −32.67% settles Nov 17
- Oct 13, 20264w ago 144 Neutral 3/10 Entry $20.76 to $16.16 Now $14.53 −30.01% ▼ −22.16% −20.89% vs SPY
- Sep 30, 20266w ago 144 Neutral 3/10 Entry $23.72 to $21.24 Now $14.53 −38.74% ▼ −10.46% −11.16% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers